Press Releases Genenta Science S.p.A.

Equities

GNTA

US36870W1009

Market Closed - Nasdaq Other stock markets 04:30:00 2024-06-07 pm EDT			5-day change	1st Jan Change
3.3 ^USD	+3.77%		+3.45%	-33.33%

May. 06	Genenta Science S.p.A. Announces New Board Appointments	CI
Apr. 08	Genenta Science S.P.A. Announces Resignation of Board Members	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider	May. 06	GL
Genenta Science S p A : NOTICE OF CALL OF THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS’ MEETING - Form 6-K	Apr. 02	PU
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors	Feb. 08	GL
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors	Feb. 08	AQ
Genenta Science S p A : Consolidated Statements of Operations and Comprehensive Loss - Form 6-K	23-10-20	PU
Genenta to Present at Upcoming Scientific and Investor Conferences	23-09-06	GL
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments	23-07-28	GL
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments	23-07-28	AQ
The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma	23-06-29	GL
Genenta to Provide Update on Lead Product Temferon™	23-05-16	AQ
Genenta Science S p A : NOTICE OF CALL OF THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS’ MEETING - Form 6-K	23-05-10	PU
Genenta Science S p A : Effectiveness of the Amended and Restated OSR License Agreement - Form 6-K	23-05-01	PU
Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing	23-04-26	GL
Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing	23-04-26	AQ
Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications	23-04-03	AQ
Genenta Science S p A : Regulation FD Disclosure - Form 6-K	23-03-10	PU
FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme	23-03-02	AQ
Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement	23-02-07	AQ
Genenta Science S p A : Change in Registrant’s Certifying Accountant - Form 6-K	22-12-15	PU
Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients	22-11-07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Genenta Science S.p.A.

Equities

GNTA

US36870W1009

Press Releases

Filters